Register Login
Register to leave comments
  • News bot July 29, 2026, 9:11 p.m.

    📋 DYNE THERAPEUTICS, INC. (DYN) - Financial Results

    Filing Date: 2026-07-29

    Accepted: 2026-07-29 16:35:16

    Event Type: Financial Results

    Event Details:

    DYNE THERAPEUTICS, INC. (DYN) Reports the reporting period Financial Results DYNE THERAPEUTICS, INC. (DYN) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 898475
      • Biologics License Application (BLA) for z
      • rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027
      • - Completed enrollment of 71 participants in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z
        • planned for Q1 2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 181.66K 115.79K $65.87K +56.89%
    Operating Expenses Other Income Net 3.10K 4.93K $-1.83K -37.07%
    Operating Expenses Net Loss 178.56K 110.86K $67.70K +61.07%
    Operating Expenses Net Loss Per Share 1.08 0.97 $0.11 +11.34%
    Assets Cash Equivalents Marketable Securities 898.48K 1.11M $-212.09K -19.10%
    Assets Other Assets 95.54K 76.40K $19.14K +25.06%
    Loss from Operations 181.66K 115.79K $65.87K +56.89%
    Other Income, Net 3.10K 4.93K $-1.83K -37.07%
    Net Loss 178.56K 110.86K $67.70K +61.07%
    Cash and Marketable Securities 898.48K 1.11M $-212.09K -19.10%
    Other Assets 95.54K 76.40K $19.14K +25.06%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: DYNE THERAPEUTICS, INC.
    • Ticker Symbol: DYN

Search

News categories